Comparison of raltegravir and elvitegravir on HIV-1 integrase catalytic reactions and on a series of drug-resistant integrase mutants

Biochemistry

Volumn 47, Issue 36, 2008, Pages 9345-9354

  Marinello, Jessica ^a   Marchand, Christophe ^a   Mott, Bryan T ^b   Bain, Anjali ^b   Thomas, Craig J ^b   Pommier, Yves ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NUCLEIC ACIDS;

HIV-1 INTEGRASE; INTEGRASE; INVERSE CORRELATION; MEDIATED REACTIONS;

SETTLING TANKS;

ELVITEGRAVIR; INTEGRASE; MUTANT PROTEIN; OLIGONUCLEOTIDE; RALTEGRAVIR;

ARTICLE; DRUG ACTIVITY; DRUG EFFECT; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME MECHANISM; ENZYME PURIFICATION; HUMAN IMMUNODEFICIENCY VIRUS 1; PRIORITY JOURNAL; VIRUS MUTANT; VIRUS RESISTANCE;

AMINO ACID SUBSTITUTION; CATALYSIS; DNA, VIRAL; DRUG RESISTANCE, VIRAL; HIV INTEGRASE; HIV INTEGRASE INHIBITORS; HIV-1; MUTATION, MISSENSE; PROTEIN BINDING; PYRROLIDINONES; QUINOLONES; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 51549116289     PISSN: 00062960     EISSN: None     Source Type: Journal    
DOI: 10.1021/bi800791q     Document Type: Article

References (29)

1. Zolopa, A., Mullen, M., Berger, D., Ruane, P., Hawkins, T., Zhong, L., Chuck, S., Enejosa, J., Kearney, B., and Cheng, A. (2007)The HIV integrase inhibitor GS-9137 demonstrates potent ARV activity in treatment-experienced patients, 14th Conf. Retrovir. Opportun. Infect. Abstract, 143LB.
2. Evering, T. H., and Markowitz, M. (2008) Raltegravir: an integrase inhibitor for HIV-1. Expert Opin. Invest. Drugs 17, 413-422.
3. Dayam, R., Gundla, R., Al-Mawsawi, L. Q., and Neamati, N. (2008) HIV-1 integrase inhibitors: 2005-2006 update. Med. Res. Rev. 28, 118-154.
4. Turlure, F., Devroe, E., Silver, P. A., and Engelman, A. (2004) Human cell proteins and human immunodeficiency virus DNA integration. Front. Biosci. 9, 3187-3208.
5. Pommier, Y., Johnson, A. A., and Marchand, C. (2005) Integrase inhibitors to treat HIV/AIDS. Nat. Rev. 4, 236-248.
6. Craigie, R., Mizuuchi, K., Bushman, F. D., and Engelman, A. (1991) A rapid in vitro assay for HIV DNA integration. Nucleic Acids Res. 19, 2729-2734.
7. Marchand, C., Neamati, N., and Pommier, Y. (2001) In vitro human immunodeficiency virus type 1 integrase assays. Methods Enzymol. 340, 624-633.
8. Fesen, M. R., Kohn, K. W., Leteurtre, F., and Pommier, Y. (1993) Inhibitors of human immunodeficiency virus integrase. Proc. Natl. Acad. Sci. U.S.A. 90, 2399-2403.
9. Hazuda, D. J., Miller, M. D., Nguyen, B. Y., and Zhao, J. (2007) Resistance to the HIV-integrase inhibitor raltegravir: analysis of protocol 005, a Phase II study in patients with triple-class resistant HIV-1 infection, Antiviral Ther. 12, Abstract 8.
10. Shimura, K., Kodama, E., Sakagami, Y., Matsuzaki, Y., Watanabe, W., Yamataka, K., Watanabe, Y., Ohata, Y., Doi, S., Sato, M., Kano, M., Ikeda, S., and Matsuoka, M. (2008) Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137). J. Virol. 82, 764-774.
11. Johnson, A. A., Marchand, C., Patil, S. S., Costi, R., Di Santo, R., Burke, T. R., Jr., and Pommier, Y. (2007) Probing HIV-1 integrase inhibitor binding sites with position-specific integrase-DNA cross-linking assays. Mol. Pharmacol. 71, 893-901.
12. Johnson, A. A., Sayer, J. M., Yagi, H., Patil, S. S., Debart, F., Maier, M. A., Corey, D. R., Vasseur, J. J., Burke, T. R., Jr., Marquez, V. E., Jerina, D. M., and Pommier, Y. (2006) Effect of DNA modifications on DNA processing by HIV-1 integrase and inhibitor binding: role of DNA backbone flexibility and an open catalytic site. J. Biol. Chem. 281, 32428-32438.
13. Chow, S. A., Vincent, K. A., Ellison, V., and Brown, P. O. (1992) Reversal of integration and DNA splicing mediated by integrase of human immunodeficiency virus. Science (New York) 255, 723-726.
14. Miller, M., Witmer, M., Stillmock, K., Felock, P., Ecto, L., Flynn, J., Schleif, W., Dornadula, G., Danovich, R., and Hazuda, D. (2006)Biochemical and antiviral activity of MK-0518, a potent HIV integrase inhibitor, XVI International AIDS Conference, Abstract THAA0302.
15. Sato, M., Motomura, T., Aramaki, H., Matsuda, T., Yamashita, M., Ito, Y., Kawakami, H., Matsuzaki, Y., Watanabe, W., Yamataka, K., Ikeda, S., Kodama, E., Matsuoka, M., and Shinkai, H. (2006) Novel HIV-1 integrase inhibitors derived from quinolone antibiotics. J. Med. Chem. 49, 1506-1508.
16. Ren, C., May, S., Miletti, T., and Bedard, J. (2007)In vitro cross-resistance studies of five different classes of integrase inhibitors in recombinant HIV-1, Antiviral Ther. 12, Abstract 1.
17. Malet, I., Delelis, O., Valantin, M. A., Montes, B., Soulie, C., Wirden, M., Tchertanova, L., Peytavin, G., Reynes, J., Mouscadet, J. F., Katlama, C., Marcelin, A. G., and Calvez, V. (2007)Biochemical characterizations of the effect of mutations selected in HIV-1 integrase gene associated with failure to raltegravir (MK-0518), Antiviral Ther. 12, Abstract 7.
18. Jones, G., Ledford, R., Yu, F., Miller, M., Tsiang, M., and McColl, D. (2007)Resistance profile fo HIV-1 mutants in vitro selected by the HIV-1 intergase inhibitor GS-9137 (JTK-303), 14th Conf. Retrovir. Opportun. Infect., Abstract 627.
19. McColl, D. J., Fransen, S., Gupta, S., Parkin, N., Margot, N., Chuck, S., Cheng, A. K., and Miller, M. D. (2007)Resistance and cross-resistance to first generation integrase inhibitors: insights from a Phase II study of elvitergavir (GS-9137), Antiviral Ther. 12, Abstract 9.
20. Hombrouck, A., Voet, A., Van Remoortel, B., Desadeleer, C., De Maeyer, M., Debyser, Z., and Witvrouw, M. (2008) Mutations in HIV-1 Integrase Confer Resistance to the Naphthyridine L-870,810 and Cross Resistance to the Clinical Trial drug GS-9137. Antimicrob. Agents Chemother. 52, 2069-2078.
21. Malet, I., Delelis, O., Valantin, M. A., Montes, B., Soulie, C., Wirden, M., Tchertanov, L., Peytavin, G., Reynes, J., Mouscadet, J. F., Katlama, C., Calvez, V., and Marcelin, A. G. (2008) Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro. Antimicrob. Agents Chemother. 52, 1351-1358.
22. Grobler, J. A., Stillmock, K., Hu, B., Witmer, M., Felock, P., Espeseth, A. S., Wolfe, A., Egbertson, M., Bourgeois, M., Melamed, J., Wai, J. S., Young, S., Vacca, J., and Hazuda, D. J. (2002) Diketo acid inhibitor mechanism and HIV-1 integrase: Implications for metal binding in the active site of phosphotransferase enzymes. Proc. Natl. Acad. Sci. U.S.A. 99, 6661-6666.
23. Marchand, C., Johnson, A. A., Karki, R. G., Pais, G. C., Zhang, X., Cowansage, K., Patel, T. A., Nicklaus, M. C., Burke, T. R., Jr., and Pommier, Y. (2003) Metal-Dependent Inhibition of HIV-1 Integrase by {beta}-Diketo Acids and Resistance of the Soluble Double-Mutant (F185K/C280S). Mol. Pharmacol. 64, 600-609.
24. Pommier, Y., and Cherfils, J. (2005) Interfacial protein inhibition: a nature's paradigm for drug discovery. Trends Pharmacol. Sci. 28, 136-145.
25. Hazuda, D. J., Felock, P., Witmer, M., Wolfe, A., Stillmock, K., Grobler, J. A., Espeseth, A., Gabryelski, L., Schleif, W., Blau, C., and Miller, M. D. (2000) Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science (New York) 287, 646-650.
26. Nicastri, E., Sarmati, L., d'Ettorre, G., Palmisano, L., Parisi, S. G., Uccella, I., Rianda, A., Concia, E., Vullo, V., Vella, S., and Andreoni, M. (2003) Replication capacity, biological phenotype, and drug resistance of HIV strains isolated from patients failing antiretroviral therapy. J. Med. Virol. 69, 1-6.
27. Mammano, F., Petit, C., and Clavel, F. (1998) Resistance-associated loss of viral fitness in human immunodeficiency virus type 1: phenotypic analysis of protease and gag coevolution in protease inhibitor-treated patients. J. Virol. 72, 7632-7637.
28. Martinez-Picado, J., Savara, A. V., Sutton, L., and D'Aquila, R. T. (1999) Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1. J. Virol. 73, 3744-3752.
29. Maignan, S., Guilloteau, J. P., Zhou-Liu, Q., Clement-Mella, C., and Mikol, V. (1998) Crystal structures of the catalytic domain of HIV-1 integrase free and complexed with its metal cofactor: high level of similarity of the active site with other viral integrases. J. Mol. Biol. 282, 359-368.